Bulletin
Investor Alert

Jasper Therapeutics Inc.

NAS: JSPR

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Jasper Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

May 20, 2022, 6:21 p.m.

JSPR
/zigman2/quotes/206872721/composite

$

3.01

Change

-0.12 -3.83%

Volume

Volume 217

Quotes are delayed by 20 min

/zigman2/quotes/206872721/composite

Today's close

$ 3.15

$ 3.13

Change

-0.02 -0.63%

Day low

Day high

$3.13

$3.36

Open

52 week low

52 week high

$2.45

$18.88

Open

Company Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene th...

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Valuation

Price to Book Ratio

4.27

Enterprise Value to EBITDA

-0.76

Efficiency

Liquidity

Current Ratio

10.95

Quick Ratio

10.95

Cash Ratio

10.56

Profitability

Return on Assets

-31.38

Return on Equity

-39.82

Return on Total Capital

-48.39

Capital Structure

Total Debt to Total Assets

3.07

Officers and Executives

Name Age Officer Since Title
Mr. Ronald A. Martell 59 2022 President & Chief Executive Officer
Mr. Jeet Mahal 49 2019 Chief Financial & Business Officer
Dr. Wendy Pang - 2020 Vice President-Research & Translational Medicine
Dr. Luca Di Noto - 2020 Vice President-Technical Operations

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/21/2022 William Lis
See Remarks; Director 		89,972   Award at $0 per share. 0
09/24/2021 Metalmark Capital LLC
2,300,000   Derivative/Non-derivative trans. at $0 per share. 0
09/24/2021 Metalmark Capital LLC
2,300,000   Derivative/Non-derivative trans. at $0 per share. 0
09/24/2021 Metalmark Capital LLC
2,300,000   Derivative/Non-derivative trans. at $0 per share. 0
09/24/2021 Metalmark Capital LLC
2,300,000   Derivative/Non-derivative trans. at $0 per share. 0
04/23/2021 Glazer Capital LLC
151,719   Disposition at $9.92 per share. 1,505,052
04/21/2021 Glazer Capital LLC
1,164   Disposition at $9.92 per share. 11,546
04/19/2021 Glazer Capital LLC
2,060   Disposition at $9.97 per share. 20,538
02/22/2021 Glazer Capital LLC
698   Disposition at $10.5 per share. 7,329
02/19/2021 Glazer Capital LLC
2,112   Disposition at $10.5 per share. 22,176
02/18/2021 Glazer Capital LLC
10,000   Disposition at $10.45 per share. 104,500
02/05/2021 Glazer Capital LLC
212   Disposition at $10.4 per share. 2,204
01/14/2021 Glazer Capital LLC
101   Disposition at $10.4 per share. 1,050
/news/latest/company/us/jspr

MarketWatch News on JSPR

  2. Jasper Therapeutics started at outperform with $19 stock price target at BMO Capital

    8:35 a.m. Oct. 20, 2021

    - Tomi Kilgore

  4. Jasper Therapeutics started at outperform with $21 stock price target at Oppenheimer

    8:44 a.m. Oct. 13, 2021

    - Tomi Kilgore

/news/nonmarketwatch/company/us/jspr

Other News on JSPR

  1. 10-Q: JASPER THERAPEUTICS, INC.

    4:28 p.m. May 12, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  3. 10-K: JASPER THERAPEUTICS, INC.

    4:21 p.m. March 18, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  8. RIOT, XERS and NNVC among pre market gainers

    9:36 a.m. Nov. 15, 2021

    - Seeking Alpha

  10. WIMI, BBVA and IONQ among pre market gainers

    8:39 a.m. Oct. 29, 2021

    - Seeking Alpha

  13. 2 Biotech Stocks Poised for Jaw-Dropping Growth

    7:45 a.m. Oct. 17, 2021

    - Motley Fool

  14. Wall Street Breakfast: What Moved Markets

    7:47 a.m. Oct. 16, 2021

    - Seeking Alpha

  15. FUTU, WTRH and BWEN among midday movers

    1:45 p.m. Oct. 15, 2021

    - Seeking Alpha

  16. Jasper Therapeutics climbs ahead of Oppenheimer summit

    10:46 a.m. Oct. 15, 2021

    - Seeking Alpha

  17. SESN, BWEN and CETX among mid-day movers

    12:53 p.m. Oct. 14, 2021

    - Seeking Alpha

  18. Jasper Therapeutics soars on Oppenheimer outperform initiation

    12:46 p.m. Oct. 13, 2021

    - Seeking Alpha

  20. STAB, RLX and GWH among mid-day movers

    12:31 p.m. Oct. 13, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Jasper Therapeutics, Inc.

2200 Bridge Parkway

Suite 102

Redwood City, California 94065

Phone

1 6505491400

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

N/A

Net Income

$-30.64M

Employees

25.00

Annual Report for JSPR

/news/pressrelease/company/us/jspr

Press Releases on JSPR

  21. Loading more headlines...
Link to MarketWatch's Slice.